TP53 and small cell carcinoma: For instance, the mutated TP53 in prostate neuroendocrine cells can inactivate the CXCL8-CXCR2-p53 pathway that universally inhibits cellular proliferation, leading to the development of small-cell neuroendocrine carcinoma (SCNC) [31].